Odyssey Therapeutics, Inc. (ODTX)

Odyssey Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 12, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Debt / Equity Ratio	0.05	0.10	0.20	0.14	0.16
Net Debt / Equity Ratio	-0.68	0.32	0.26	0.58	1.38
Net Debt / EBITDA Ratio	1.71	1.01	0.75	1.19	1.60
Net Debt / FCF Ratio	2.15	1.18	0.83	1.30	1.77
Asset Turnover	0.00	0.01	0.02	0.00	0
Quick Ratio	10.98	6.85	4.55	8.47	10.57
Current Ratio	11.36	7.20	4.77	8.72	10.91
Return on Equity (ROE)	-50.28%	-85.52%	-72.27%	-53.31%	-50.47%
Return on Assets (ROA)	-45.16%	-66.84%	-56.83%	-44.47%	-40.44%
Return on Invested Capital (ROIC)	-205.38%	-328.53%	-257.29%	-224.23%	-273.89%
Return on Capital Employed (ROCE)	-49.02%	-76.20%	-63.22%	-47.87%	-43.45%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 12, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Buyback Yield / Dilution	-1383.37%	-245.30%	-35.78%	-44.71%	-
Total Shareholder Return	-1383.37%	-245.30%	-35.78%	-44.71%	-

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Aug 5, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 7, 2026

Data Sources Report a data error